Sarah L. Grinde, VP, Development and Research at ROCHESTER MEDICAL CORPORATION (ROCM), bought 500 shares at $9.90 ($5K) on 2012-12-12, disclosed to the SEC on 2012-12-14.
Open-market purchase of $5k ROCM by VP, Development and Research. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.